Altered Functional Status of the Hypothalamic Dopaminergic Tone in Patients with Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Study

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 5, 2006, Pages 566-572

  Parra, Adalberto ^a   Ramírez Peredo, Jorge ^a   Hidalgo, Rocío ^a   Morales Toquero, Amelia ^b,c   Velásquez Ramírez, Gabriela ^b   Ruiz Argüelles, Alejandro ^b   Ruiz Argüelles, Guillermo J ^b,c  

^a INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

Author keywords

Dopaminergic tone; Graft versus host disease; Hematopoietic stem cell transplantation; Prolactin

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARNOTPRIM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOPAMINE; FLUDARABINE; METHOTREXATE; METOCLOPRAMIDE; PREDNISOLONE; PREDNISONE; PROLACTIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHOLESTASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOPAMINERGIC TRANSMISSION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPOTHALAMUS; MALE; PILOT STUDY; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE;

ADULT; AGE FACTORS; ANEMIA, APLASTIC; AREA UNDER CURVE; BODY MASS INDEX; CHRONIC DISEASE; DOPAMINE; DOPAMINE ANTAGONISTS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; LEUKEMIA; MALE; METOCLOPRAMIDE; MIDDLE AGED; PILOT PROJECTS; PITUITARY GLAND, ANTERIOR; PROLACTIN; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33745457680     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.12.035     Document Type: Article

References (50)

1. Thomas E.D. Hematopoietic stem cell transplantation. Sci Am 272 (1995) 38-47
2. Ruiz-Argüelles G.J., and Gómez-Almaguer D. Braking dogmata to help patients. non-myeloablative hamatopoietic stem cell transplantation. Expert Opin Biol Ther 4 (2004) 1693-1699
3. Lunn R.A., Sumar N., Bansal A.S., and Treleaven J. Cytokine profiles in stem cell transplantation. possible use as a predictor of graft-versus-host disease. Hematology 10 (2005) 107-114
4. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 21 (2003) 149-161
5. Krenger W., and Ferrara J.L. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 15 (1996) 50-73
6. Hinterberger-Fischer M., Kier P., Spona J., et al. Prolactin. a possible mediator of graft-versus-host disease following allogeneic bone marrow transplantation in humans. Bone Marrow Transplant 14 (1994) 403-406
7. Hinterberger-Fischer M., Ogris E., Kier P., et al. Elevation of plasma prolactin in patients undergoing autologous blood stem-cell transplantation for breast cancer. is its modulation a step forward posttransplant immunotherapy?. Am J Clin Oncol 23 (2000) 325-329
8. Ben-Jonathan N., Mershon J.L., Allen D.L., and Steinmetz R.W. Extrapituitary prolactin. distribution, regulation, functions, and clinical aspects. Endocr Rev 17 (1996) 639-669
9. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation 4 (1997) 171-180
10. Matera L., and Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-gamma by natural killer and T cells. Ann N Y Acad Sci 917 (2000) 505-513
11. Reber P.M. Prolactin and immunomodulation. Am J Med 95 (1993) 637-644
12. Berczi I., Nagy E., Kovacks K., and Horvath E. Regulation of humoral immunity in rats by pituitary hormones. Acta Endocrinol 98 (1981) 506-513
13. Nagy E., Berczi I., and Friesen H.G. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol 102 (1983) 351-357
14. Neidhart M. Elevated serum prolactin or elevated prolactin/cortisone ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 23 (1996) 476-481
15. Jara L.J., Gómez-Sánchez C., Silveira L.H., Martínez-Osuna P., Vasey F.B., and Espinosa L.R. Hyperprolactinemia in systemic lupus erythematosus. association with disease activity. Am J Med Sci 202 (1992) 222-226
16. Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci 59 (1996) 599-614
17. Clevenger C.V., Freier D.O., and Kline J.B. Prolactin receptor signal transduction in cells of the immune system. J Endocrinol 157 (1998) 187-197
18. Matera L., Mori M., Geuna M., Buttiglieri S., and Palestro G. Prolactin in autoimmunity and antitumor defence. J Neuroimmunol 109 (2000) 47-55
19. Welniak L.A., Richards S.M., and Murphy W.J. Effects of prolactin on hematopoiesis. Lupus 10 (2001) 700-705
20. Richards S.M., and Murphy W.J. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J Neuroimmunol 109 (2000) 56-62
21. Sun R., Gault R.A., Welniak L.A., Tian Z.G., Richards S., and Murphy W.J. Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice. Biol Blood Marrow Transplant 9 (2003) 426-434
22. Ben-Jonathan N. Dopamine. a prolactin-inhibiting hormone. Endocr Rev 6 (1985) 564-589
23. Quigley M.E., Judd S.J., Gilliland G.B., and Yen S.S.C. Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and in women with hyperprolactinemic anovulation. J Clin Endocrinol Metab 48 (1979) 718-720
24. Parra A., Ramírez-Peredo J., Larrea F., et al. Decreased endogenous dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Clin Endocrinol (Oxf) 54 (2001) 731-738
25. Birnbacher R., Scheibenreiter S., Blau N., Bieglmayer C., Frisch H., and Waldhauser F. Hyperprolactinemia, a tool in treatment control of tetrahydrobiopterin deficiency. endocrine studies in an affected girl. Pediatr Res 43 (1998) 472-477
26. Ben-Jonathan N., Mershon J.L., Allen D.L., and Steinmetz R.W. Extrapituitary prolactin. distribution, regulation, functions, and clinical aspects. Endocr Rev 17 (1996) 639-669
27. Nagy E., and Berczi I. Hypophysectomized rats depend on residual prolactin for survival. Endocrinology 128 (1991) 2776-2784
28. Yen S.S.C. Prolactin in human reproduction. In: Yen S.S.C., and Jaffe R.B. (Eds). Reproductive Endocrinology. 3rd ed. (1991), Saunders, Philadelphia 357-388
29. Kessinger A., Armitage J.O., Landmark J.D., Smith D.M., and Weisenburger D.D. Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 71 (1998) 723-727
30. Ruiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 50 (1992) 735-743
31. Ruiz-Argüelles A., and Orfao A. Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles G.J., and San-Miguel J.F. (Eds). Actualización en Leucemias (1996), Editorial Médica Panamericana, Mexico City 79-82
32. Ruiz-Argüelles G.J., Gómez-Almaguer D., Ruiz-Argüelles A., González-Llano O., Cantú O.G., and Jaime-Pérez J.C. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 66 (2001) 241-244
33. Ruiz-Argüelles G.J., Gómez-Almaguer D., López-Martínez B., Cantú-Rodríguez O.G., Jaime-Pérez J.C., and González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 87 (2002) 894-896
34. Ruiz-Argüelles G.J. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens. results of the Mexican approach. Int J Hematol 76 suppl 1 (2002) 376-379
35. Gómez-Almaguer D., Ruiz-Argüelles G.J., Tarín-Arzaga L.C., et al. Reduced-intensity stem cell transplantation in children and adolescents. the Mexican experience. Biol Blood Marrow Transplant 9 (2003) 157-161
36. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy. harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
37. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 91 (1998) 756-763
38. Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol 79 (2004) 209-215
39. Pinkel D., Straume T., and Gray J.W. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci U S A 83 (1996) 2934-2938
40. Ruiz-Argüelles G.J., López-Martínez B., Santellán-Olea M.R., et al. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen. a prospective study in a single institution. Leuk Lymphoma 43 (2002) 1509-1511
41. Yam P., Petz L., Knowlton R., et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 43 (1987) 399-407
42. Parra A., Barrón J., Sinibaldi J., Coria I., and Espinosa de los Monteros A. Differences in the metoclopramide-induced prolactin release related to age at first full-term pregnancy or nulliparity. Hum Reprod 12 (1997) 214-219
43. Tai M.M. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17 (1994) 152-154
44. Takemoto M., Morishita M., Higuchi K., Yoshida J., and Aono T. Effects of body weight on responses of serum prolactin to metoclopramide and thyrotrophin releasing hormone in secondary amenorrheic women. Hum Reprod 9 (1994) 800-805
45. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Obesity Technical Report Series 894 (2000), World Health Organization, Geneva
46. Espinosa de los Monteros A., Cornejo J., and Parra A. Differential prolactin response to oral metoclopramide in nulliparous versus parous women throughout the menstrual cycle. Fertil Steril 55 (1991) 885-889
47. Méndez I., Alcocer-Varela J., Parra A., et al. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus. a possible role of lymphocyte-derived prolactin. Lupus 13 (2004) 45-53
48. McMurray R., Keisler D., Kanuckel K., Izui S., and Walker S.E. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 147 (1991) 3780-3787
49. Berczi I., Baragar F.D., Chalmers I.M., Keystone E.C., Nagy E., and Warrington R.J. Hormones in self tolerance and autoimmunity. a role in the pathogenesis of rheumatoid arthritis?. Autoimmunity 16 (1993) 45-46
50. Walker S.E. Prolactin, a pituitary hormone that modifies immune responses. Lupus 7 (1998) 371-375